| Literature DB >> 24735767 |
Khinh Ranh Voong, Kelli McSpadden, Chelsea C Pinnix, Ferial Shihadeh, Valerie Reed, Mohammad R Salehpour, Isidora Arzu, He Wang, David Hodgson, John Garcia, Michalis Aristophanous, Bouthaina S Dabaja1.
Abstract
PURPOSE: High cure rates for Hodgkin's lymphoma must be balanced with long-term treatment-related toxicity. Here we report an intensity-modulated radiation therapy (IMRT) technique that achieves adequate target coverage for mediastinal disease while minimizing high- and low-dose exposure of critical organs. METHODS AND MATERIALS: Treatment plans for IMRT and conventional anteroposterior-posteroanterior (AP-PA) techniques, with comparable coverage of the planning target volume (PTV), were generated for 9 female patients with mediastinal Hodgkin's lymphoma assuming use of inclined positioning, daily breath-hold, and CT-on-rails verification. Our "butterfly" IMRT beam arrangement involved anterior beams of 300°-30° and posterior beams of 160°-210°. Percentages of normal structures receiving 30 Gy (V30), 20 Gy (V20), and 5 Gy (V5) were tabulated for the right and left breasts, total lung, heart, left and right ventricles, left anterior descending coronary artery (LAD), and spinal cord. Differences in each variable, conformity index, homogeneity index, and V107% between the two techniques were calculated (IMRT minus conventional).Entities:
Mesh:
Year: 2014 PMID: 24735767 PMCID: PMC4013438 DOI: 10.1186/1748-717X-9-94
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Figure 1Display of the patient’s immobilization set-up during treatment simulation. Arrows point to hip stopper (1), Vac-Lok (2), inclined board (3), and facemask (4).
Figure 2Axial CT treatment-planning scan shows beam angles for the butterfly technique.
Mean percent volumes of organs at risk receiving 30, 25, 20, or 5 Gy and mean dose to organs at risk via anteroposterior-posteroanterior (AP-PA) or butterfly intensity-modulated radiation therapy (IMRT) techniques
| Right breast | V30 | 0.5% | 1.9% | −1.4% | 0.01 |
| V25 | 1.9% | 3.1% | −1.2% | 0.03 | |
| V20 | 3.8% | 3.7% | 0.1% | 0.44 | |
| V5 | 13.7% | 7.5% | 6.2% | 0.01 | |
| Mean Dose, Gy | 2.28 | 1.92 | 0.36 | 0.26 | |
| Left breast | V30 | 1.2% | 2.9% | −1.7% | 0.02 |
| V25 | 2.8% | 4.2% | −1.4% | 0.01 | |
| V20 | 4.0% | 4.9% | −0.9% | 0.01 | |
| V5 | 11.2% | 8.4% | 2.8% | 0.01 | |
| Mean Dose, Gy | 2.42 | 2.38 | 0.04 | 0.41 | |
| Right ventricle | V30 | 12.3% | 28.7% | −16.4% | 0.01 |
| V25 | 21.7% | 33.4% | −11.7% | 0.01 | |
| V20 | 27.4% | 35.8% | −8.4% | 0.01 | |
| V5 | 41.2% | 42.7% | −1.5% | 0.17 | |
| Mean Dose, Gy | 10.25 | 12.16 | −1.91 | 0.09 | |
| Left ventricle | V30 | 7.3% | 9.7% | −2.4% | 0.28 |
| V25 | 2.6% | 15.8% | −13.2% | 0.01 | |
| V20 | 4.6% | 18.8% | −14.2% | 0.01 | |
| V5 | 21.5% | 29.7% | −8.2% | 0.21 | |
| Mean Dose, Gy | 4.13 | 7.72 | −3.59 | 0.02 | |
| Left anterior descending artery | V30 | 21.5% | 28.5% | −7.0% | 0.28 |
| V25 | 26.4% | 38.2% | −11.8% | 0.01 | |
| V20 | 28% | 42.2% | −14.2% | 0.01 | |
| V5 | 51.8% | 51.7% | 0.1% | 0.55 | |
| Mean Dose, Gy | 10.44 | 14.46 | −4.02 | 0.02 | |
| Heart | V30 | 16.8% | 29% | −12.2% | 0.01 |
| V25 | 23.8% | 35.7% | −11.9% | 0.01 | |
| V20 | 28.3% | 38.8% | −10.5% | 0.01 | |
| V5 | 42.5% | 46.0% | −3.5% | 0.34 | |
| Mean Dose, Gy | 11.52 | 14.26 | −2.74 | 0.01 | |
| Total lung | V30 | 4.8% | 19.5% | −14.6% | 0.01 |
| V25 | 15.4% | 26.5% | −11.1% | 0.01 | |
| V20 | 22.2% | 29.9% | −7.7% | 0.01 | |
| V5 | 54.0% | 41.1% | 12.9% | 0.17 | |
| Mean Dose, Gy | 9.25 | 11.31 | −2.06 | 0.01 | |
| Spinal cord | V30 | 5.6% | 57.8% | −52.2% | 0.01 |
| V25 | 35.3% | 61.7% | −25.4% | 0.01 | |
| V20 | 50.4% | 63.8% | −13.4% | 0.01 | |
| V5 | 75.6% | 75.7% | −0.1% | 0.86 | |
| Mean Dose, Gy | 17.16 | 21.93 | −4.77 | 0.01 |
*P values generated by the Wilcoxon match-pairs signed-rank test for non-parametric comparisons.
Comparison of the mean conformity index, homogeneity index, V , PTV dose, and monitor units delivered per fraction for anteroposterior-posteroanterior (AP-PA) or butterfly intensity-modulated radiation therapy (IMRT) techniques
| RTOG Conformity Index (V100%/VPTV) | 1.10 | 1.66 | −0.56 | 0.37 |
| RTOG Homogeneity Index (Imax/RI) | 1.15 | 1.14 | 0.01 | 0.89 |
| V107%, cm3 | 47.7 | 801.5 | −753.8 | 0.01 |
| PTV dose, Gy | 31.39 | 32.02 | −0.63 | 0.01 |
| Monitor Units per Fraction | 797 | 208 | 589 | 0.01 |
Imax is the maximum isodose or maximum point dose. RI is the reference isodose or 30.6 Gy.
*P values generated by the Wilcoxon match-pairs signed-rank test for non-parametric comparisons.
Figure 3Mean volumes of organs at risk receiving 0, 5, 10, 15, 20, 25, 30, or 35 Gy.
Figure 4Coronal (A), sagittal (B), and axial (C) views of a butterfly intensity-modulated radiation therapy (IMRT) plan (left) and plan using anteroposterior-posteroanterior (AP-PA) photon beams (right). Red isodose lines represent 30.6 Gy; orange, 20 Gy; green, 10 Gy; and purple 5 Gy. The clinical target volume (shaded green) includes initial sites of nodal involvement. The Butterfly IMRT plan limits the 30.6-Gy dose to the breasts (panel C).